[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX355760B - Formulaciones gástricas y colónicas y métodos para elaborar y usar las mismas. - Google Patents

Formulaciones gástricas y colónicas y métodos para elaborar y usar las mismas.

Info

Publication number
MX355760B
MX355760B MX2013006641A MX2013006641A MX355760B MX 355760 B MX355760 B MX 355760B MX 2013006641 A MX2013006641 A MX 2013006641A MX 2013006641 A MX2013006641 A MX 2013006641A MX 355760 B MX355760 B MX 355760B
Authority
MX
Mexico
Prior art keywords
methods
formulations
alternative embodiments
compositions
gastric
Prior art date
Application number
MX2013006641A
Other languages
English (en)
Other versions
MX2013006641A (es
Inventor
Julius Borody Thomas
Saxon John
Ramrakha Sanjay
Wettstein Antony
Original Assignee
Salix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Inc filed Critical Salix Pharmaceuticals Inc
Publication of MX2013006641A publication Critical patent/MX2013006641A/es
Publication of MX355760B publication Critical patent/MX355760B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

En modalidades alternativas, la invención proporciona composiciones, por ejemplo, formulaciones, usadas para tratamientos gástricos, gastrointestinales y/o colónicos o lavados, por ejemplo, lavado ortostático, por ejemplo, para inducir la purga (por ejemplo, limpieza) de un tracto gastrointestinal (por sus siglas en inglés, GI), que incluye un colon; y métodos para elaborar y usar las mismas. En modalidades alternativas, composiciones y métodos de la invención se usan para el alivio, tratamiento y/o prevención de estreñimiento, para el tratamiento de dolor abdominal, particularmente dolor abdominal no específico, y diarrea, que incluye diarrea causada por un efecto secundario de fármaco, una condición fisiológica, una enfermedad o una condición tal como enfermedad de Crohn, un veneno, una toxina o una infección, por ejemplo, la diarrea del viajero mediada por toxina. En modalidades alternativas, la invención proporciona farmacéuticos y productos (artículos) de manufactura para suministrar estas composiciones y formulaciones a un individuo, por ejemplo, un humano o un animal.
MX2013006641A 2010-12-13 2011-12-13 Formulaciones gástricas y colónicas y métodos para elaborar y usar las mismas. MX355760B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42256710P 2010-12-13 2010-12-13
PCT/AU2011/001609 WO2012079118A1 (en) 2010-12-13 2011-12-13 Gastric and colonic formulations and methods for making and using them

Publications (2)

Publication Number Publication Date
MX2013006641A MX2013006641A (es) 2013-11-04
MX355760B true MX355760B (es) 2018-04-27

Family

ID=46243884

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006641A MX355760B (es) 2010-12-13 2011-12-13 Formulaciones gástricas y colónicas y métodos para elaborar y usar las mismas.

Country Status (15)

Country Link
US (2) US10092573B2 (es)
EP (1) EP2651415B1 (es)
JP (1) JP6121334B2 (es)
KR (1) KR101947720B1 (es)
CN (2) CN110200954A (es)
AU (1) AU2011342368B2 (es)
BR (1) BR112013014827A2 (es)
CA (1) CA2821196C (es)
DK (1) DK2651415T3 (es)
IL (1) IL226831B (es)
MX (1) MX355760B (es)
NZ (1) NZ611868A (es)
PL (1) PL2651415T3 (es)
SG (1) SG191145A1 (es)
WO (1) WO2012079118A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS088702A0 (en) * 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
US10092573B2 (en) 2010-12-13 2018-10-09 Salix Pharmaceuticals, Inc. Gastric and colonic formulations and methods for making and using them
KR20140090217A (ko) * 2011-10-27 2014-07-16 토마스 줄리어스 보로디 전해액 하제
HUE043852T2 (hu) * 2012-07-27 2019-09-30 Redhill Biopharma Ltd A vastagbél kiürítésére szolgáló készítmények és a készítmények elõállítási módszerei
RU2015111258A (ru) * 2012-08-29 2016-10-20 Саликс Фармасьютикалз, ИНК. Слабительные композиции и способы лечения запора и связанных с ним желудочно-кишечных заболеваний и состояний
CN108904462A (zh) 2013-03-15 2018-11-30 布伦特里实验室公司 双用途硫酸盐口服药物组合物片剂及其使用方法
JP6394142B2 (ja) * 2013-07-25 2018-09-26 大正製薬株式会社 固形製剤
WO2015056897A1 (ko) * 2013-10-17 2015-04-23 강윤식 장 세정용 조성물
KR101423005B1 (ko) * 2013-10-17 2014-07-28 강윤식 장 세정용 조성물
CN103550212A (zh) * 2013-11-03 2014-02-05 王显著 含匹可硫酸和抗坏血酸的药物组合物
CN107205928B (zh) * 2014-11-04 2021-05-11 因华生技制药股份有限公司 不稳定或难溶药物的口服投予
GB201511255D0 (en) * 2015-06-26 2015-08-12 Colltec Ltd Formulation
CN107847511B (zh) * 2015-07-14 2021-03-26 国立大学法人大阪大学 强直性肌营养不良治疗药
CN106910184B (zh) * 2017-01-12 2020-10-09 杭州电子科技大学 基于深度卷积神经网络的内窥镜图像肠道出血检测方法
US10143656B1 (en) * 2017-08-04 2018-12-04 Braintree Laboratories, Inc. Solid oral sulfate salt formulations for cleaning a colon and methods of using same
MX2020007462A (es) 2018-01-12 2020-09-14 Metimedi Pharmaceuticals Co Ltd Metodos de tratamiento de enfermedades inflamatorias cronicas.
KR102111094B1 (ko) * 2018-06-18 2020-05-14 주식회사 한국팜비오 무수황산나트륨, 황산칼륨, 무수황산마그네슘 및 시메티콘을 포함하는 장관하제 경구투여용 고형제제 조성물
CN108904808A (zh) * 2018-08-15 2018-11-30 西安力邦医药科技有限责任公司 一种治疗便秘的药物组合物及其应用
CN109289095B (zh) * 2018-11-23 2021-03-26 淮海工学院 一种含盐酸利多卡因的肠镜凝胶剂及其制备方法
MX2021009841A (es) * 2019-02-15 2021-12-15 Seaford Pharmaceuticals Inc Administracion oral de cloruro de sodio para prevenir complicaciones asociadas a la limpieza intestinal con laxantes estimulantes.
WO2021150638A1 (en) * 2020-01-20 2021-07-29 Advanced Health Solutions LLC Compositions and methods for improving visibility of the gastrointestinal tract for endoscopy procedures
US11554155B2 (en) 2020-01-20 2023-01-17 Advanced Health Solutions LLC Compositions and methods for improving gastrointestinal function
CN111494313A (zh) * 2020-05-25 2020-08-07 李会芳 一种用于母猪便秘治疗的灌肠液及其制备方法
WO2022093170A1 (en) * 2020-10-26 2022-05-05 Braintree Laboratories, Inc. Sulfate salt formulations for colon cleansing
CN112587498A (zh) * 2020-12-29 2021-04-02 哈尔滨瀚钧现代制药有限公司 多库酯钠丹蒽醌及其制备方法
KR102669683B1 (ko) * 2020-12-31 2024-05-28 주식회사태준제약 장세척을 위한 경구용 고형제제

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA761927A (en) * 1967-06-27 Seeger Ernst Benzoxazine derivatives
US4186025A (en) 1975-09-25 1980-01-29 Merck & Co., Inc. Aqueous polysaccharide composition
US4452779A (en) 1982-02-03 1984-06-05 Cockerill Vernon Composition and method of treating lactating mammals
JPS58222020A (ja) 1982-06-18 1983-12-23 Teijin Ltd 前処置用下剤
DK454683D0 (da) 1983-10-03 1983-10-03 Mogens Gjerloev Tarmreguleringsmiddel til behandling af diarre hos dyr samt anvendelse heraf
WO1986005981A1 (en) 1985-04-18 1986-10-23 Borody Thomas J Treatment of non-ulcer dyspepsia with bismuth salts
US4766004A (en) 1986-12-19 1988-08-23 Warner-Lambert Company Crunchy, highly palatable, bulk-increasing, dietary fiber supplement composition
IL86859A (en) 1987-07-10 1991-12-15 E Z Em Inc Aqueous cathartic solution containing inorganic salts
EP0439453B1 (en) 1987-10-12 1994-01-19 Exomed Australia Pty. Ltd. (ACN 051 976 446) Improved method for treatment of gastrointestinal disorders
US5274001A (en) 1987-12-24 1993-12-28 Borody Thomas J Orthostatic lavage solutions
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
CA1333564C (en) 1988-08-02 1994-12-20 Thomas Julius Borody Treatment of gastro-intestinal disorders
US5213807A (en) 1990-05-03 1993-05-25 Chemburkar Pramod B Pharmaceutical composition containing ibuprofen and a prostaglandin
US5232699A (en) 1990-07-26 1993-08-03 The Proctor & Gamble Company Laxative compositions
US5519014A (en) 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
EP0554291B2 (en) 1990-10-22 2010-10-20 Centre For Digestive Diseases Pty Ltd Treatment of non-inflammatory bowel disorders
US5173296A (en) 1990-11-16 1992-12-22 The Procter & Gamble Company Compositions containing psyllium
JP3047143B2 (ja) 1992-04-24 2000-05-29 堀井薬品工業株式会社 腸管洗浄液用組成物及び腸管洗浄液
WO1995011024A1 (en) 1993-10-19 1995-04-27 The Procter & Gamble Company Picosulphate dosage form
JP3850891B2 (ja) 1994-03-01 2006-11-29 ゼリア新薬工業株式会社 緩下効果を有する組成物
AUPM695294A0 (en) 1994-07-20 1994-08-11 Borody, Thomas Julius Improved combination therapy dose unit
AUPM864894A0 (en) 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
JP3010007B2 (ja) 1995-05-22 2000-02-14 ビオフェルミン製薬株式会社 配合下剤
RU2098100C1 (ru) 1995-10-11 1997-12-10 Максимова Ирина Сергеевна Ирригационный раствор для офтальмологических операций
AUPN634595A0 (en) 1995-11-03 1995-11-30 Borody, Thomas Julius Improved method for colonic evacuation
NZ333493A (en) 1995-11-03 2000-06-23 Nicolas Peter Shortis Method of evacuating a patient's colon by oral administration of an osmotic colonic evacuant in powder form
US6103268A (en) 1995-11-03 2000-08-15 Borody; Thomas Julius Administering osmotic colonic evacuant containing a picosulfate
AU771576B2 (en) 1995-11-03 2004-03-25 Red Hill Biopharma Ltd. Improved preparation for colonic evacuation
JP3423842B2 (ja) 1996-01-19 2003-07-07 日研化学株式会社 変異株及び該変異株又は親株を用いるエリスリトールの製造方法
US6087386A (en) 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
EP0845538B1 (en) 1996-12-02 2003-04-02 Mitsubishi Chemical Corporation Method of producing erythritol
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
KR19980075195A (ko) 1997-03-26 1998-11-16 손경식 트리코스포로노이데스 속 변이균주 및 이를 이용한 에리스리톨의 제조방법
US6162464A (en) 1997-03-31 2000-12-19 Inkine Pharmaceutical, Inc. Non-aqueous colonic purgative formulations
US6277836B1 (en) 1997-04-01 2001-08-21 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
US6551632B2 (en) 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
CN1252711A (zh) * 1997-04-18 2000-05-10 大正制药株式会社 微乳
AUPO665397A0 (en) 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
JP4092748B2 (ja) 1997-09-05 2008-05-28 ニプロ株式会社 腸管洗浄液
KR100541578B1 (ko) 1997-12-04 2006-04-06 미쓰비시 가가꾸 가부시키가이샤 에리트리톨 생산방법
PL197989B1 (pl) 1997-12-19 2008-05-30 Smithkline Beecham Corp Sposób wytwarzania szybko rozpraszających się tabletek do podawania doustnego, szybko rozpraszający się preparat farmaceutyczny w postaci tabletek i szybko rozpraszająca się, farmaceutycznie dopuszczalna, tabletka do podawania doustnego
AUPP325398A0 (en) 1998-04-30 1998-05-21 Borody, Thomas J. Improved method for eradicating h. pylori
AUPP437698A0 (en) 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
US6001616A (en) 1998-09-16 1999-12-14 Dong Cheon Consulting Co., Ltd. Process for preparing erythritol using novel cell of pichia
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
DE60040214D1 (de) 1999-02-26 2008-10-23 Shionogi & Co Kaubare weichkapseln mit verbesserten verabreichungseigenschaften sowie verfahren zu deren herstellung
US6858403B2 (en) 1999-05-11 2005-02-22 M-Biotech, Inc. Polymer matrix containing catalase co-immobilized with analytic enzyme that generates hydrogen peroxide
DE19930030B4 (de) 1999-06-30 2004-02-19 Meduna Arzneimittel Gmbh CO-3-ungesättigte Fettsäuren enthaltende orale Darreichungsform
CN1288730A (zh) 1999-09-07 2001-03-28 麦克内尔-Ppc股份有限公司 轻泻组合物
JP2001114668A (ja) 1999-10-13 2001-04-24 Meiji Seika Kaisha Ltd チョコレート剤
US6774111B1 (en) 2000-03-14 2004-08-10 Abbott Laboratories Carbohydrate system and a method for providing nutrition to a diabetic
JP2003531171A (ja) 2000-04-19 2003-10-21 トーマス ジュリアス ボロディー 高脂血症関連疾患に対する組成物および治療
CN1444484A (zh) 2000-06-19 2003-09-24 穆科普罗泰科有限公司 用益生菌对粘膜表面的细菌或病毒感染进行治疗或免疫治疗及用于此的组合物
AUPQ854100A0 (en) 2000-07-03 2000-07-27 Helirad Pty Ltd Methods for monitoring treatment of helicobacter infection
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
ATE354969T1 (de) 2001-03-13 2006-03-15 Kellog Co Belüftete nahrungsmittelkomponente
US6790453B2 (en) 2001-03-14 2004-09-14 Mccormick & Company, Inc. Encapsulation compositions and process for preparing the same
US7815956B2 (en) 2001-04-27 2010-10-19 Pepsico Use of erythritol and D-tagatose in diet or reduced-calorie beverages and food products
IL159129A0 (en) 2001-06-01 2004-05-12 Pozen Inc PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
AU2002315779B2 (en) 2001-07-05 2007-03-22 Wakunaga Pharmaceutical Co.,Ltd Soft capsules
US20030092724A1 (en) 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
AUPS017702A0 (en) 2002-01-25 2002-02-14 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders
AUPS088702A0 (en) 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
US6753009B2 (en) * 2002-03-13 2004-06-22 Mcneil-Ppc, Inc. Soft tablet containing high molecular weight polyethylene oxide
CA2478523A1 (en) 2002-04-05 2003-10-16 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US6946149B2 (en) 2002-04-30 2005-09-20 Braintree Laboratories, Inc. Salt solution for colon cleansing
AU2003900553A0 (en) 2003-02-10 2003-02-20 Borody, Thomas Julius Novel Improved Method for Detection of Dientamoeba fragilis and other Parasites
JP4458761B2 (ja) 2003-03-27 2010-04-28 ロート製薬株式会社 瀉下用製剤
CN1767855A (zh) * 2003-04-08 2006-05-03 普罗热尼奇制药公司 包含缓泻剂和外周阿片拮抗剂的便秘的组合疗法
NZ544007A (en) * 2003-05-07 2009-05-31 Samyang Corp Highly plastic granules for making fast melting tablets
US7687075B2 (en) 2003-11-19 2010-03-30 Salix Pharmaceuticals, Ltd. Colonic purgative composition with soluble binding agent
JP2008503445A (ja) * 2004-04-13 2008-02-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 便秘患者におけるシメチコンの使用
AU2004320512A1 (en) 2004-06-04 2005-12-22 Braintree Laboratories, Inc. Method of bowel cleansing
KR100749229B1 (ko) * 2005-04-29 2007-08-13 (주)아모레퍼시픽 당 및 당알콜을 함유하는 변비개선용 조성물
US20060275223A1 (en) 2005-06-02 2006-12-07 Burr James B Erythritol compositions for teeth and gums
WO2007057924A1 (en) 2005-11-21 2007-05-24 Panacea Biotec Ltd Laxative composition on the basis of triphala
WO2007073702A2 (es) 2005-12-29 2007-07-05 Osmotica Corp. Comprimido multicapa con combinación de triple liberación
US20070185145A1 (en) 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
CN101033010A (zh) * 2006-03-09 2007-09-12 麦迪森企业股份有限公司 塑料容器的内容物封装方法及其容器的制造流程
JP5006567B2 (ja) 2006-04-14 2012-08-22 花王株式会社 口腔用固形製剤
WO2008021394A2 (en) * 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
WO2008027442A2 (en) 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
JP2008115085A (ja) 2006-11-01 2008-05-22 Tendou Seiyaku Kk 緩下剤
WO2008141368A1 (en) 2007-05-17 2008-11-27 David Lubowski Combination laxative compositions comprising a colonic stimulant and a bulking laxative
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
KR101903781B1 (ko) 2007-06-06 2018-11-13 바스프 에스이 급속 붕해 정제의 제조를 위한 제약 제제
WO2008148734A1 (de) 2007-06-06 2008-12-11 Basf Se Pharmazeutische formulierung für die herstellung von kau- und lutsch-tabletten
EP2183262A1 (en) 2007-07-27 2010-05-12 Cargill, Incorporated Micronization of polyols
US20100233278A1 (en) 2007-09-27 2010-09-16 Akiko Ookawa Rapidly disintegrating solid preparation
US9623010B2 (en) 2007-10-01 2017-04-18 Laboratorios Lesvi, S.L. Orodispersible tablets
BRPI0816513A2 (pt) 2007-10-19 2015-03-24 Purdue Research Foundation Composição farmacêutica e método para preparar a suspensão sólida
JP5258268B2 (ja) 2007-11-19 2013-08-07 フロイント産業株式会社 球形粒の製造方法
US20090155363A1 (en) 2007-12-14 2009-06-18 Todd Maibach Methods for oral administration of active drugs
US9314454B2 (en) 2007-12-28 2016-04-19 Sawai Pharmaceutical Co., Ltd. Oral cavity disintegrating tablet and method of producing the same
US20090258090A1 (en) 2008-04-11 2009-10-15 Braintree Laboratories, Inc. Colon cleansing solution
US20100178413A1 (en) 2008-12-17 2010-07-15 Mark Gorris Food-based Supplement Delivery System
US20100285164A1 (en) 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
WO2010138439A1 (en) 2009-05-28 2010-12-02 Aptapharma, Inc. Multiparticulate controlled-release selective serotonin reuptake inhibitor formulations
US20110218216A1 (en) 2010-01-29 2011-09-08 Kumaravel Vivek Extended release pharmaceutical composition of donepezil
US10092573B2 (en) 2010-12-13 2018-10-09 Salix Pharmaceuticals, Inc. Gastric and colonic formulations and methods for making and using them
KR20140090217A (ko) 2011-10-27 2014-07-16 토마스 줄리어스 보로디 전해액 하제
HUE043852T2 (hu) 2012-07-27 2019-09-30 Redhill Biopharma Ltd A vastagbél kiürítésére szolgáló készítmények és a készítmények elõállítási módszerei
RU2015111258A (ru) 2012-08-29 2016-10-20 Саликс Фармасьютикалз, ИНК. Слабительные композиции и способы лечения запора и связанных с ним желудочно-кишечных заболеваний и состояний

Also Published As

Publication number Publication date
JP6121334B2 (ja) 2017-04-26
WO2012079118A1 (en) 2012-06-21
AU2011342368B2 (en) 2016-11-17
AU2011342368A1 (en) 2013-05-09
CN103338768A (zh) 2013-10-02
EP2651415B1 (en) 2020-10-07
SG191145A1 (en) 2013-07-31
MX2013006641A (es) 2013-11-04
EP2651415A4 (en) 2014-04-23
IL226831B (en) 2018-02-28
PL2651415T3 (pl) 2021-04-19
CA2821196A1 (en) 2012-06-21
DK2651415T3 (da) 2020-11-30
KR20140018210A (ko) 2014-02-12
CA2821196C (en) 2022-11-22
BR112013014827A2 (pt) 2016-10-04
EP2651415A1 (en) 2013-10-23
NZ611868A (en) 2015-11-27
CN103338768B (zh) 2019-04-19
US10092573B2 (en) 2018-10-09
KR101947720B1 (ko) 2019-02-14
US20190240229A1 (en) 2019-08-08
JP2014502598A (ja) 2014-02-03
US20130296314A1 (en) 2013-11-07
CN110200954A (zh) 2019-09-06

Similar Documents

Publication Publication Date Title
MX355760B (es) Formulaciones gástricas y colónicas y métodos para elaborar y usar las mismas.
EP3424515A3 (en) Stool collection devices and methods for using them
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
IN2012DN06720A (es)
PH12017500023A1 (en) Targeted conjugates and particles and formulations thereof
EA200701519A1 (ru) Живая аттенуированная ротавирусная вакцина для перорального введения
EP3904502A3 (en) Compositions and methods
BR112014024159A2 (pt) Formulações de vacina oral específicas do local gastrintestinal , ativas no íleo e apêndice.
MY186106A (en) Diagnosis, prevention and treatment of diseases of the joint
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
UA104320C2 (ru) Фармацевтическая композиция на основе митохондриально-адресованного антиоксиданта для применения в медицинской и ветеринарной офтальмологии
MX2019002669A (es) Composicion farmaceutica para usarse en el tratamiento de la malnutricion en un sujeto que exhibe un trastorno de espectro de autismo (asd).
MX336774B (es) Moduladores alostericos positivos de receptores m1 de la quinolina amida.
UY27627A1 (es) Aza - arilpiperazinas
EP3818991A3 (en) Compositions and methods for treating diseases
MX2023010328A (es) Composiciones de medicamentos a base de peptido de colageno y metodos y dispositivos para su produccion y uso.
EA201100565A1 (ru) Композиции и способы лечения заболеваний кишечника с использованием гранулированного мезаламина
WO2011151722A3 (en) Methods and compositions for oral pharmaceutical therapy
MX2019006867A (es) Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de integrina.
ATE544354T1 (de) Vermeidung und behandlung von mikrobenübertragenen epithelerkrankungen
WO2014030049A3 (en) Compositions comprising a single variable domain and camostat mesylate (cm)
EA201491272A1 (ru) Нанопродукт, содержащий lactobacillus reuteri dan080, подходящий для профилактики и терапии - человеческой и ветеринарной, и его медицинское применение
EP4309722A3 (en) Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
EA200970614A1 (ru) Средства для стимуляции продуцирования iga

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: SALIX PHARMACEUTICALS, INC.

FG Grant or registration